We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, OXIS International Inc. (GTBP - Free Report) closed at $12.51, marking a +1.54% move from the previous day. This move outpaced the S&P 500's daily loss of 0.25%.
Heading into today, shares of the company had gained 34.94% over the past month, outpacing the Medical sector's gain of 1.44% and the S&P 500's gain of 1.26% in that time.
Wall Street will be looking for positivity from GTBP as it approaches its next earnings report date. In that report, analysts expect GTBP to post earnings of -$0.25 per share. This would mark year-over-year growth of 26.47%.
Investors should also note any recent changes to analyst estimates for GTBP. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.62% lower. GTBP is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 203, which puts it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
In the latest trading session, OXIS International Inc. (GTBP - Free Report) closed at $12.51, marking a +1.54% move from the previous day. This move outpaced the S&P 500's daily loss of 0.25%.
Heading into today, shares of the company had gained 34.94% over the past month, outpacing the Medical sector's gain of 1.44% and the S&P 500's gain of 1.26% in that time.
Wall Street will be looking for positivity from GTBP as it approaches its next earnings report date. In that report, analysts expect GTBP to post earnings of -$0.25 per share. This would mark year-over-year growth of 26.47%.
Investors should also note any recent changes to analyst estimates for GTBP. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.62% lower. GTBP is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 203, which puts it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.